Clinical Trials Browser

Phase 2/3 × Enrolling by invitation × 1 year × Clear all

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05374590 2026-02-02

ADAPT Jr +

Phase 2/3 Enrolling by invitation

Myasthenia Gravis